Literature DB >> 28100419

Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: Pathophysiological and phenotypic implications.

Fahmy T Ali1, Eman M Abd El-Azeem1, Marwa A Hamed2, Mohamed A M Ali3, Nour M Abd Al-Kader1, Ekrami A Hassan1.   

Abstract

BACKGROUND: Although a clear mechanism underlying the pathophysiology of schizophrenia (SZ) remains elusive, oxidative stress, inflammatory syndrome and immune activation have become an attractive hypothesis for explaining the pathophysiology of SZ. Data from prior studies on the role of matrix metalloproteinase 9 (MMP-9) and brain-derived neurotrophic factor (BDNF) single nucleotide polymorphisms (SNPs) in SZ are contradictory. We aimed to investigate whether oxidative stress, inflammatory and immune activation markers as well as MMP-9 levels may be implicated in SZ pathogenesis. The association of MMP-9 and BDNF SNPs with the clinical expression of SZ was examined. SUBJECTS AND METHODS: Ninety-four subjects were recruited, including 44 SZ patients and 50 healthy controls. Serum levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC), nitrite, C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), Beta-2 microglobulin (Β2M), complement component 3 (C3), C4 and MMP-9 were measured. The MMP-9 -1562C>T and BDNF196G>A SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism assay. Psychopathology was assessed using the positive and negative syndrome scale (PANSS).
RESULTS: SZ patients showed significantly higher TBARS, PCC, nitrite, CRP, IL-6, TNF-α, Β2M, C3 and MMP-9 levels than controls. In distinguishing SZ patients from healthy controls, CRP and MMP-9 yielded similar discriminatory performance, and both perform better than IL-6, Β2M, C3, nitrite, TBARS, PCC, TNF-α and C4. The MMP-9 -1562C>T SNP genotypes distribution didn't differ significantly between controls and SZ patients. As compared to controls, SZ patients harbor a significantly higher frequency of the BDNF196GG genotype and a lower frequency of the BDNF196GA/AA genotype. Patients carrying the MMP-9 -1562CC or BDNF196GG genotype revealed a significantly higher PANSS than those carrying MMP-9 -1562CT/TT or BDNF196GA/AA genotype. Male gender and the MMP-9 -1562CC genotype were identified as independent predictive factors for higher PANSS.
CONCLUSIONS: Redox dysregulation and alterations in the immuno-inflammatory pathways are major culprits in the pathogenesis of SZ. MMP-9 and BDNF SNPs are associated with the clinical phenotype of SZ and, thus, may be a useful marker predicting the phenotypic expression and prognosis of SZ patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Clinical phenotype; Matrix metalloproteinase 9; Schizophrenia; Single nucleotide polymorphisms

Mesh:

Substances:

Year:  2017        PMID: 28100419     DOI: 10.1016/j.schres.2017.01.016

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Impaired Redox Control in Autism Spectrum Disorders: Could It Be the X in GxE?

Authors:  Vanja Mandic-Maravic; Marija Pljesa-Ercegovac; Marija Mitkovic-Voncina; Ana Savic-Radojevic; Dusica Lecic-Tosevski; Tatjana Simic; Milica Pejovic-Milovancevic
Journal:  Curr Psychiatry Rep       Date:  2017-08       Impact factor: 5.285

Review 2.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

3.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

4.  Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.

Authors:  Maju Mathew Koola; Samir Kumar Praharaj; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-17

5.  The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.

Authors:  Johanna Seitz-Holland; Magdalena Seethaler; Nikos Makris; Jarrett Rushmore; Kang-Ik K Cho; Elizabeth Rizzoni; Mark Vangel; Olcay Senay Sahin; Carina Heller; Ofer Pasternak; Filip Szczepankiewicz; Carl-Fredrik Westin; Jan Lošák; Libor Ustohal; Josef Tomandl; Lubomír Vojtíšek; Petr Kudlička; Martin Jáni; T Wilson Woo; Tomáš Kašpárek; Zora Kikinis; Marek Kubicki
Journal:  Neuropsychopharmacology       Date:  2021-04-08       Impact factor: 7.853

6.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

7.  A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms.

Authors:  Katarzyna Lepeta; Katarzyna J Purzycka; Katarzyna Pachulska-Wieczorek; Marina Mitjans; Martin Begemann; Behnam Vafadari; Krystian Bijata; Ryszard W Adamiak; Hannelore Ehrenreich; Magdalena Dziembowska; Leszek Kaczmarek
Journal:  EMBO Mol Med       Date:  2017-08       Impact factor: 12.137

Review 8.  MMPs in learning and memory and neuropsychiatric disorders.

Authors:  Anna Beroun; Shiladitya Mitra; Piotr Michaluk; Barbara Pijet; Marzena Stefaniuk; Leszek Kaczmarek
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

9.  Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients.

Authors:  Paolo Enrico; Giuseppe Delvecchio; Nunzio Turtulici; Alessandro Pigoni; Filippo Maria Villa; Cinzia Perlini; Maria Gloria Rossetti; Marcella Bellani; Antonio Lasalvia; Chiara Bonetto; Paolo Scocco; Armando D'Agostino; Stefano Torresani; Massimiliano Imbesi; Francesca Bellini; Angela Veronese; Luisella Bocchio-Chiavetto; Massimo Gennarelli; Matteo Balestrieri; Gualtiero I Colombo; Annamaria Finardi; Mirella Ruggeri; Roberto Furlan; Paolo Brambilla
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

10.  Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment.

Authors:  Monika Matusiak; Dominika Oziębło; Monika Ołdak; Emilia Rejmak; Leszek Kaczmarek; Piotr Henryk Skarżyński; Henryk Skarżyński
Journal:  Mol Neurobiol       Date:  2022-01-21       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.